| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Integrative Physiology |
From the Division of Nephrology and Hypertension and Cardiovascular Kidney Hypertension Institute (D.W., P.S.G., T.C., J.R., M.M., K.D., M.L., P.M., O.A., W.J.W., C.S.W.), Georgetown University, Washington, DC; Division of Nephrology and Endocrinology (M.L.O., A.T.), University of Tokyo, Japan; Department of Medicine (J.L., P.V.), University College, London, UK; Oxonon BioAnalysis (A.L.), Emeryville, Calif. Present address for P.V.: Glaxo Smith Kline, Greenford, Middlesex, UK.
Correspondence to Christopher S. Wilcox, MD, PhD, Division of Nephrology and Hypertension, Georgetown University Medical Center, 6 PHC, Suite F6003, 3800 Reservoir Rd NW, Washington, DC 20007. E-mail wilcoxch{at}georgetown.edu
Asymmetric dimethylarginine (ADMA), which inhibits NO synthase, is inactivated by NG,NG-dimethylarginine dimethylaminohydrolase (DDAH). We tested whether DDAH-1 or -2 regulates serum ADMA (SADMA) and/or endothelium-derived relaxing factor (EDRF)/NO. Small inhibitory (si)RNAs targeting DDAH-1 or -2, or an siRNA control were given intravenously to rats. After 72 hours, EDRF/NO was assessed from acetylcholine-induced, NO synthase–dependent relaxation and 4-amino-5-methylamino-2',7'-diflouroflourescein diacetate for NO activity in isolated mesenteric resistance vessels (MRVs). Expression of mRNA for DDAH-1 versus -2 was 2- and 7-fold higher in the kidney cortex and liver, respectively, whereas expression of DDAH-2 versus -1 was 5-fold higher in MRVs. The proteins and mRNAs for DDAH-1 or -2 were reduced selectively by 35% to 85% in the kidney cortex, liver, and MRVs 72 hours following the corresponding siRNA. SADMA was increased only after siDDAH-1 (266±25 versus 342±39 [mean±SD] nmol · L–1; P<0.005), whereas EDRF/NO responses and NO activity were not changed consistently by siDDAH-1 but were greatly reduced after siDDAH-2. Mean arterial pressure was not changed significantly by any siRNA. In conclusion, SADMA is regulated by DDAH-1, which is expressed at sites of ADMA metabolism in the kidney cortex and liver, whereas EDRF/NO is regulated primarily by DDAH-2, which is expressed strongly in blood vessels. This implies specific functions of DDAH isoforms.
Key Words: RNA interference hypertension kidney blood vessel endothelium
This article has been cited by other articles:
![]() |
S. Blackwell The biochemistry, measurement and current clinical significance of asymmetric dimethylarginine Ann Clin Biochem, January 1, 2010; 47(1): 17 - 28. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. C. Sullivan, J. L. Pardieck, K. A. Hyndman, and J. S. Pollock Renal NOS activity, expression, and localization in male and female spontaneously hypertensive rats Am J Physiol Regulatory Integrative Comp Physiol, January 1, 2010; 298(1): R61 - R69. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Y. Ivashchenko, B. T. Bradley, Z. Ao, J. Leiper, P. Vallance, and D. G. Johns Regulation of the ADMA-DDAH system in endothelial cells: a novel mechanism for the sterol response element binding proteins, SREBP1c and -2 Am J Physiol Heart Circ Physiol, January 1, 2010; 298(1): H251 - H258. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. J. Pope, K. Karrupiah, P. N. Kearns, Y. Xia, and A. J. Cardounel Role of Dimethylarginine Dimethylaminohydrolases in the Regulation of Endothelial Nitric Oxide Production J. Biol. Chem., December 18, 2009; 284(51): 35338 - 35347. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. C. Richir, R. H. Bouwman, T. Teerlink, M. P.C. Siroen, T. P.G.M. de Vries, and P. A.M. van Leeuwen The Prominent Role of the Liver in the Elimination of Asymmetric Dimethylarginine (ADMA) and the Consequences of Impaired Hepatic Function JPEN J Parenter Enteral Nutr, November 1, 2008; 32(6): 613 - 621. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Sakurada, M. Shichiri, M. Imamura, H. Azuma, and Y. Hirata Nitric Oxide Upregulates Dimethylarginine Dimethylaminohydrolase-2 via Cyclic GMP Induction in Endothelial Cells Hypertension, November 1, 2008; 52(5): 903 - 909. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Dayal, R. N. Rodionov, E. Arning, T. Bottiglieri, M. Kimoto, D. J. Murry, J. P. Cooke, F. M. Faraci, and S. R. Lentz Tissue-specific downregulation of dimethylarginine dimethylaminohydrolase in hyperhomocysteinemia Am J Physiol Heart Circ Physiol, August 1, 2008; 295(2): H816 - H825. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Jacobi, R. Maas, N. Cordasic, K. Koch, R. E. Schmieder, R. H. Boger, and K. F. Hilgers Role of asymmetric dimethylarginine for angiotensin II-induced target organ damage in mice Am J Physiol Heart Circ Physiol, February 1, 2008; 294(2): H1058 - H1066. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Palm, M. L. Onozato, Z. Luo, and C. S. Wilcox Dimethylarginine dimethylaminohydrolase (DDAH): expression, regulation, and function in the cardiovascular and renal systems Am J Physiol Heart Circ Physiol, December 1, 2007; 293(6): H3227 - H3245. [Abstract] [Full Text] [PDF] |
||||
|
Circulation Research Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2007 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |